In substrate reduction therapy (SRT), the synthesis of glycosphingolipids is reduced by partial inhibition of glucosylceramide (G1cCer) synthase by deoxynojirimycin analogs (5), leading to reduction of the glycosphingolipid pool and eventually to reduction of the substrate load for lysosomal degradation by sphingolipid hydrolases.

Glucosidase inhibitors such as deoxynojirimycin (DNM) are reported to be potent antivirals and have been used in the treatment of an HIV infected lymphocyte culture, in which they inhibited the spread of the virus (Papandreou et al.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.